Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Protein Pept Lett. 2023;30(10):868-876. doi: 10.2174/0109298665255704230920063254.
The ferroptosis inhibitory gene solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) inhibit ferroptosis in carcinoma cells. However, whether SLC7A11 and GPX4 serve as an oncogene in renal cell carcinoma (RCC) remains unclear.
Immunohistochemistry (IHC) assays were performed to assess the expression of SLC7A11 and GPX4 in human RCC tissues. Clinical-pathological analysis was performed to explore the correlation between SLC7A11 and GPX4 expression. Kaplan-Meier survival analysis was performed to characterise the associations between protein expression and patient progressionfree survival (PFS).
The upregulation of SLC7A11 and GPX4 was detected by IHC in RCC tissues compared with that in normal renal tissues. Meanwhile, the expression level of SLC7A11 and GPX4 was correlated with tumour diameter and distant metastasis (P<0.05). Kaplan-Meier survival analysis indicated that patients with high SLC7A11 and GPX4 expression levels exhibited worse PFS than those with low SLC7A11 and GPX4 expression levels (P<0.05).
The upregulation of SLC7A11 and GPX4 expression was associated with poor prognosis in patients with RCC. SLC7A11 and GPX4 may serve as diagnostic and prognostic biomarkers for patients with RCC.
铁死亡抑制基因溶质载体家族 7 成员 11（SLC7A11）和谷胱甘肽过氧化物酶 4（GPX4）可抑制癌细胞中的铁死亡。然而，SLC7A11 和 GPX4 是否在肾细胞癌（RCC）中作为致癌基因尚不清楚。
通过免疫组织化学（IHC）检测 SLC7A11 和 GPX4 在人 RCC 组织中的表达。进行临床病理分析以探讨 SLC7A11 和 GPX4 表达之间的相关性。进行 Kaplan-Meier 生存分析以描述蛋白表达与患者无进展生存期（PFS）之间的关联。
与正常肾组织相比，IHC 检测到 RCC 组织中 SLC7A11 和 GPX4 的上调。同时，SLC7A11 和 GPX4 的表达水平与肿瘤直径和远处转移相关（P<0.05）。Kaplan-Meier 生存分析表明，SLC7A11 和 GPX4 高表达的患者 PFS 较 SLC7A11 和 GPX4 低表达的患者差（P<0.05）。
SLC7A11 和 GPX4 表达上调与 RCC 患者的不良预后相关。SLC7A11 和 GPX4 可能成为 RCC 患者的诊断和预后生物标志物。
Zotero 插件
